<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9062">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02988960</url>
  </required_header>
  <id_info>
    <org_study_id>M15-862</org_study_id>
    <secondary_id>2016-002219-16</secondary_id>
    <nct_id>NCT02988960</nct_id>
  </id_info>
  <brief_title>A Study of ABBV-927, an Immunotherapy, in Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927, an Immunotherapy, in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and
      pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or
      recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as
      combination therapy with nivolumab in participants with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>First dose of study drug through at least 100 days after end of treatment or until the start of another anticancer therapy; up to 2 years after last participants first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with nivolumab</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>The MTD and the RPTD of ABBV-927 when administered as monotherapy or as combination therapy with nivolumab will be determined during the dose escalation phase of the study. Once the RPTD has been determined, the dose expansion portion will begin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of ABBV-927</measure>
    <time_frame>Up to 12 weeks after participant's first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of ABBV-927</measure>
    <time_frame>Up to 12 weeks after participant's first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve (AUC) of ABBV-927</measure>
    <time_frame>Up to 12 weeks after participant's first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (t1/2) of ABBV-927</measure>
    <time_frame>Up to 4 weeks after participant's first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 30 days after and up to 24-month of treatment period</time_frame>
    <description>ORR is defined as the proportion of participants with a confirmed partial or complete response to the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response (DOR)</measure>
    <time_frame>Up to 30 days after and up to 24-month of treatment period</time_frame>
    <description>DOR is defined as the time from the initial objective response to disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR, defined as the percentage of participants with a confirmed partial, complete response, or stable disease for at least 24 weeks to the treatment)</measure>
    <time_frame>Up to 30 days after and up to 24-month of treatment period</time_frame>
    <description>CBR defined as the proportion of subjects with a confirmed partial response (PR), complete response (CR), or stable disease for at least 24 weeks to the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 30 days after and up to 24-month of treatment period</time_frame>
    <description>PFS time is defined as the time from the first dose of ABBV-927 to disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Advance Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Escalating Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-927 via intravenous administration at escalating dose levels in 28-day dosing cycles (2 doses per cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escalating Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-927 via intratumoral administration at escalating dose levels in 28-day dosing cycles (2 doses per cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escalation Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-927 via intravenous administration at escalating dose levels in combination with nivolumab in 28-day dosing cycles (2 doses per cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional participants (with squamous cell carcinoma of the head and neck [SCCHN], pancreatic adenocarcinoma, or non-small cell lung cancer [NSCLC]) will be enrolled in a dose expansion cohorts that will further evaluate ABBV-927.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Arm B1, B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional participants (with cutaneous melanoma or SCCHN) will be enrolled in a dose expansion cohorts that will further evaluate ABBV-927.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional participants with NSCLC will be enrolled in an expansion cohort that will further evaluate ABBV-927 plus nivolumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-927</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Escalating Arm 1</arm_group_label>
    <arm_group_label>Escalation Arm 3</arm_group_label>
    <arm_group_label>Expansion Arm A</arm_group_label>
    <arm_group_label>Expansion Arm B1, B2</arm_group_label>
    <arm_group_label>Expansion Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-927</intervention_name>
    <description>Intratumoral</description>
    <arm_group_label>Escalating Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab will be administered according to standard or approved doses and dosing schedules.</description>
    <arm_group_label>Escalation Arm 3</arm_group_label>
    <arm_group_label>Expansion Arm C</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0
             to 1.

          -  Participants have adequate bone marrow, kidney and liver function.

          -  Participants in all monotherapy arms must have an advanced solid tumor that has
             progressed on standard therapies known to provide clinical benefit or the
             participants are intolerant to such therapies.

          -  Participants in all combination therapy arms must have an advanced solid tumor for
             which the indicated standard of care is nivolumab.

        Exclusion Criteria:

          -  Active or prior documented autoimmune disease in the last 2 years.

          -  Current or prior use of immunosuppressive medication within 14 days prior to the
             first dose (with certain exceptions).

          -  History of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic
             leukemia, solid organ transplantation, or previous clinical diagnosis of
             tuberculosis.

          -  Prior grade greater than or equal to 3 immune-mediated neurotoxicity or pneumonitis
             while receiving immunotherapy.

          -  Known uncontrolled malignancy of the central nervous system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie_Call Center</last_name>
    <phone>847-283-8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155265</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 155265, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 158654</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 158654, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155263</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 155263, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155266</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 155266, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 7, 2017</lastchanged_date>
  <firstreceived_date>December 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic adenocarcinoma</keyword>
  <keyword>Non-small cell lung cancer (NSCLC)</keyword>
  <keyword>Squamous cell carcinoma of the head and neck (SCCHN)</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Cutaneous melanoma</keyword>
  <keyword>Advanced solid tumor</keyword>
  <keyword>Cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
